Premium
Frequent activation of AKT2 kinase in human pancreatic carcinomas
Author(s) -
Altomare Deborah A.,
Tanno Satoshi,
De Rienzo Assunta,
KleinSzanto Andres J.,
Tanno Sachie,
Skele Kristine L.,
Hoffman John P.,
Testa Joseph R.
Publication year - 2002
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.10287
Subject(s) - akt2 , protein kinase b , cancer research , pten , pi3k/akt/mtor pathway , carcinogenesis , pancreatic cancer , ca19 9 , biology , cancer , signal transduction , pathology , medicine , akt1 , microbiology and biotechnology
Activation of AKT/protein kinase B promotes a variety of biological activities important in tumorigenesis, such as cell survival and cell cycle progression. We previously demonstrated amplification and overexpression of the AKT2 gene in a subset of human pancreatic carcinomas. In this investigation, we assessed AKT2 catalytic activity in 50 frozen pancreatic tissues (37 carcinomas, four benign tumors, and nine normal pancreata) by in vitro kinase assay. Twelve of 37 (32%) pancreatic carcinomas showed markedly elevated levels of AKT2 activity compared to normal pancreata and benign pancreatic tumors. To delineate mechanisms contributing to AKT2 activation in malignant pancreatic tumors, we examined the status of upstream components of the phosphatidylinositol 3‐kinase (PI3K)/AKT pathway. Western blot analysis revealed loss of PTEN protein expression in two of the 12 pancreatic carcinomas with activated AKT2. In vitro PI3K assays demonstrated high levels of PI3K activity in seven carcinoma specimens that showed AKT2 activation. Immunohistochemical staining confirmed high levels of phosphorylated (active) AKT in malignant pancreatic tumors compared to normal pancreata. Overall, these data suggest that upstream perturbations of the PI3K/AKT pathway contribute to frequent activation of AKT2 in pancreatic cancer, which may contribute to the pathogenesis of this highly aggressive form of human malignancy. J. Cell. Biochem. 87: 470–476, 2002. © 2002 Wiley‐Liss, Inc.